Company: PTPI
Filing Date: 2025-06-20
Form Type: 8-K
Source: 0001104659-25-061230
Chunk: 2

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-06-20
Form: 8-K
Item: Item 7.01
Chunk 2
---
, 2025. The unaudited pro forma condensed consolidated financial
information has been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of
operations in future periods or the results that actually would have been realized after giving effect to the Assignment.

In accordance with General Instruction B.2 of Form 8-K, the information
in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933,
as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item
7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein,
including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit      Description                                                                  
   Number                                                                                   
 ────────────────────────────────────────────────────────────────────────────────────────────
     99.1      Unaudited Pro Forma Financial Information of Petros Pharmaceuticals, Inc.    
      104      Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

                           PETROS PHARMACEUTICALS, INC.                                                     
  Date: June 20, 2025      By:                               /s/ Fady Boctor                                
                                                             Name: Fady Boctor                              
                                                             Title: President and Chief Commercial Officer